SPEC PerkinElmer 11.10
|Articles|April 20, 2009

Mass Spectrometry and Glial Cells

Using a new mass spectrometry technique and stem cells that can be made to produce either neurons or glial cells, a team of researchers at the Salk Institute for Biological Studies (La Jolla, California) identified a molecular signaling pathway that is required for the production of glial cells, yielding insight into the neurobiology of Down?s syndrome and several nervous system disorders characterized by too many glial cells.

Using a new mass spectrometry technique and stem cells that can be made to produce either neurons or glial cells, a team of researchers at the Salk Institute for Biological Studies (La Jolla, California) identified a molecular signaling pathway that is required for the production of glial cells, yielding insight into the neurobiology of Down’s syndrome and several nervous system disorders characterized by too many glial cells.

Their findings indicate that synaptojanin-1, a central component of the pathway, is essential to the production of glia, brain cells that act as neurons’ personal assistants. According to Salk professor David Schubert, who heads the Cellular Neurobiology Laboratory, “The discovery of this molecular signaling pathway promises to completely change the way we think about central nervous system maladies, allowing the development of drugs that inhibit glial proliferation and improve the prognosis of patients with a host of devastating conditions.”

In addition to Down’s syndrome, increased production of glial cells is seen in such conditions as Alzheimer’s disease, stroke, other neurodegenerative disorders, and glioblastoma, the most common and malignant of brain tumors. Also, a surplus of glial cells has been found to be detrimental to the regeneration of nerves following spinal injury.


Related to this article

Spectral Frontiers: Seeing the Unseeable Microspectroscopy
Microspectroscopy, the marriage of spectroscopic chemical identification with microscopic spatial resolution, has advanced from Perkin-Elmer's first commercial infrared microspectrometer in 1953 to today's nanoscale AFM-IR probes, synchrotron-brightness infrared beamlines, and compact hyperspectral tissue imaging devices being developed for AI-assisted cancer detection.
Atoms Don't Lie–The Remaking of Atomic Spectroscopy, © Hallie -chronicles-stock.adobe.com
Atomic spectroscopy has quietly gone from counting elements in bulk to counting single nanoparticles, imaging tissue at the micrometer scale, and reading Martian rocks from several meters away. The instruments got smaller, the software got smarter, and the questions they can now answer got a lot more interesting.
Work of the surgeon in the hospital operating room. Concentrated doctor with glasses. | Image Credit: © velimir - stock.adobe.com
Jürgen Popp explains how head and neck surgeons in Jena use a Raman probe to locate tumor borders, why the technique could replace frozen section biopsies, and why optical tools must adapt to clinical workflows rather than the other way around.